Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events : A Secondary Analysis of the PEGASUS-TIMI 54 Trial

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F16%3A00066623" target="_blank" >RIV/65269705:_____/16:00066623 - isvavai.cz</a>
Result on the web
<a href="http://jamanetwork.com/journals/jamacardiology/fullarticle/2528235" target="_blank" >http://jamanetwork.com/journals/jamacardiology/fullarticle/2528235</a>
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events : A Secondary Analysis of the PEGASUS-TIMI 54 Trial
Original language description
IMPORTANCE: In the PEGASUS-TIMI 54 trial, treatment with ticagrelor reduced the incidence of cardiovascular death, myocardial infarction, or stroke by 15% to 16% among stable patients compared with placebo. However, more patients prematurely discontinued treatment with ticagrelor than with placebo. OBJECTIVE: To investigate the reasons and timing of discontinuation of treatment with ticagrelor among stable patients prior myocardial infarction. DESIGN, SETTING, AND PARTICIPANTS: In the PEGASUS-TIMI 54 trial, 21 162 stable outpatients with prior myocardial infarction were randomly assigned to 90 mg of ticagrelor twice daily, 60 mg of ticagrelor twice daily, or placebo, with all of the patients receiving a low dose of aspirin. These participants were followed up for a median of 33 months (study start date: October 2010; completion date: December 2014). Discontinuation of treatment was evaluated by treatment arm, cause, and timing. This analysis was initiated in May 2015.
Czech name
—
Czech description
—

Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)